{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is an AE reported for the first time or the worsening of a pre-existing event after the first dose of study drug.","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set-MDS: all participants with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasm (MPN) overlap syndromes who received at least 1 dose of zilurgisertib","reportingStatus":"POSTED","timeFrame":"up to 950 days","title":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}